Three AI deals kick off #JPM22 weekend; Can Silicon Valley change how science gets funded?; Special report: 2021 new drug approvals; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
A notable trend in this week’s installment of news is a hearty plate of appetizer-sized deals as we lead into the JP Morgan conference. As per Endpoints tradition, we have scheduled three days of virtual panels featuring an excellent lineup of biopharma insiders to talk about the top trends they will be watching in 2022. You don’t want to miss it.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,700+ biopharma pros reading Endpoints daily — and it's free.